USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: VASADE BIOSCIENCES, INC.
City: North Brunswick
State: NJ
Zip+4: 08902-
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $505,790.00 3
SBIR Phase II $1,620,985.00 1
STTR Phase I $547,371.00 4
STTR Phase II $1,883,238.00 2

Award List:

Prevention of cardiac cell death by Mst1 inhibitor

Award Year / Program / Phase: 2005 / STTR / Phase I
Agency: HHS
Research Institution: UMDNJ
Principal Investigator: Junichi Sadoshima
Award Amount: $141,802.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): Growing lines of evidence suggest that cardiac myocyte death, including apoptosis, is intimately involved in the pathogenesis of heart failure. Thus, an important therapeutic objective in reducing morbidity and mortality in patients with heart diseases is to… More

Primate Model for Pharmaceutical Development

Award Year / Program / Phase: 2005 / STTR / Phase I
Agency: HHS
Research Institution: UMDNJ-NEW JERSEY MEDICAL SCHOOL
Principal Investigator: Youtang Shen
Award Amount: $126,225.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): With the advances in molecular medicine and genome projects showing many promising opportunities for new strategies of treating human diseases, the number of small pharmaceutical/biotech companies has increased steeply during the past several years. While the… More

Primate Model for Pharmaceutical Development

Award Year / Program / Phase: 2007 / STTR / Phase II
Agency: HHS
Research Institution: UMDNJ-NJMS
Principal Investigator: Youtang Shen
Award Amount: $776,051.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): Advances in molecular medicine and genomic research promise to produce exciting new strategies for the treatment of human diseases. One significant concern regarding preclinical research data is that the results may not be predictive of future clinical outcomes.… More

AntimiR-199a for cardiac ischemia and failure

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: Mariana S. Delorenzo
Award Amount: $132,191.00
Abstract:
DESCRIPTION (provided by applicant): Protecting the heart against ischemia or ischemia/reperfusion injury is one of the top health care objectives. Currently, one of the most effective mechanisms is ischemia preconditioning, which is achieved by intermitt ent occlusion of the coronary artery via… More

AC5 Inhibitor for Obesity

Award Year / Program / Phase: 2010 / STTR / Phase I
Agency: HHS
Research Institution: Univ Of Med/ Dent Of Nj-Sch/Hlth Rel Pro
Principal Investigator: Dorothy E. Vatner – 973-972-1339
Award Amount: $133,845.00
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): The goal of this proposal is to develop a drug that will be therapeutic for obesity and diabetes and improve exercise tolerance. Obesity, diabetes and exercise are inextricably linked such that an agent that improves exercise tolerance or prevents obesity or the… More

Prevention of Cardiac Cell Death by Mst1 inhibitor

Award Year / Program / Phase: 2010 / STTR / Phase II
Agency: HHS
Research Institution: Univ Of Med/ Dent Of Nj-Sch/Hlth Rel Pro
Principal Investigator: Junichi Sadoshima – 973-972-8619
Award Amount: $1,107,187.00
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): 6. Abstract Almost 20 million people suffer from ischemic heart diseases in US and one million patients develop myocardial infarction (MI) every year. Many patients develop heart failure even if they survive the acute event, which clearly indicates that current… More

Acute Coronary Syndrome animal model

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Patricio Abarzua – 609-618-0565
Award Amount: $167,930.00
Abstract:
DESCRIPTION (provided by applicant): Most new therapeutic measures that protect infarct size in experimental animals have failed in the clinics, to a large extent because they are only effective when administered prior to coronary artery occlusion. Our preliminary data indicate that an adenylyl… More

AC5 inhibitor for heart failure

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Patricio Abarzua – 973-953-4377
Award Amount: $205,669.00
Abstract:
DESCRIPTION (provided by applicant): Cardiovascular disease is a critical health issue in the US and Western countries. The leading cause of death is heart failure (HF). Almost 5.5 million patients are diagnosed with congestive HF in the U.S and the majorcause of HF is myocardial ischemic disease.… More

AC5 inhibitor for heart failure

Award Year / Program / Phase: 2013 / SBIR / Phase II
Agency: HHS
Principal Investigator: Patricio Abarzua – 973-420-3259
Award Amount: $1,620,985.00
Abstract:
DESCRIPTION (provided by applicant): Cardiovascular disease is a critical health issue in the US and Western countries. The leading cause of death is heart failure (HF). Almost 5.5 million patients are diagnosed with congestive HF in the U.S and the majorcause of HF is myocardial ischemic disease.… More